BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31086539)

  • 1. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan.
    Tahir M; Bashir U; Hafeez J; Ghafoor R
    Pak J Med Sci; 2019; 35(2):495-499. PubMed ID: 31086539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
    Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
    J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of oral itraconazole and intramuscular meglumine antimoniate in the treatment of cutaneous leishmaniasis.
    Saleem K; Rahman A
    J Coll Physicians Surg Pak; 2007 Dec; 17(12):713-6. PubMed ID: 18182133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
    López L; Robayo M; Vargas M; Vélez ID
    Trials; 2012 May; 13():58. PubMed ID: 22594858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis.
    Tunalı V; Harman M; Çavuş İ; Gündüz C; Özbilgin A; Turgay N
    Acta Parasitol; 2021 Jun; 66(2):354-360. PubMed ID: 32996014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miltefosine in cutaneous leishmaniasis.
    Rahman SB; ul Bari A; Mumtaz N
    J Coll Physicians Surg Pak; 2007 Mar; 17(3):132-5. PubMed ID: 17374296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
    Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis.
    Kämink S; Masih B; Ali N; Ullah A; Khan SJ; Ashraf S; Pylypenko T; Grobusch MP; Fernhout J; den Boer M; Ritmeijer K
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008988. PubMed ID: 33507944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
    Tayyebi M; Darchini-Maragheh E; Layegh P; Kiafar B; Goyonlo VM
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009241. PubMed ID: 33739976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
    Costa Filho AV; Lucas IC; Sampaio RN
    Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
    Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
    Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis.
    Ware JM; O'Connell EM; Brown T; Wetzler L; Talaat KR; Nutman TB; Nash TE
    Clin Infect Dis; 2021 Oct; 73(7):e2457-e2562. PubMed ID: 33124666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
    Coelho AC; Trinconi CT; Costa CH; Uliana SR
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.
    Machado PRL; Prates FVO; Boaventura V; Lago T; Guimarães LH; Schriefer A; Corte TWF; Penna G; Barral A; Barral-Netto M; Carvalho EM
    Clin Infect Dis; 2021 Oct; 73(7):e2465-e2469. PubMed ID: 32894278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
    Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
    Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
    Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
    Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.